Do we need a different set of response assessment criteria for tumor immunotherapy?

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7116-7118

  Ribas, Antoni ^a,b   Chmielowski, Bartosz ^a   Glaspy, John A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 73149111448     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2376     Document Type: Note

References (8)

1. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
3. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008;105:3005-10.
4. Ribas A, Comin-Anduix B, Economou JS, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 2009;15:390-9.
5. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-6.
6. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-81.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [see comments]. J Natl Cancer Inst 2000;92:205-16.
8. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.